HIV prevention and treatment remain a top public health priority in New York City, which continues to report some of the highest HIV diagnosis rates in the United States. For residents seeking affordable, reliable PrEP or HIV treatment, Tafero EM — the Indian generic equivalent of Truvada and Descovy — provides identical clinical efficacy at a fraction of the branded cost.
Tafero EM contains Emtricitabine 200mg and Tenofovir Alafenamide 25mg, two antiretrovirals that together suppress HIV-1 viral replication while protecting kidney and bone health better than older TDF-based formulations. When taken daily as PrEP, it reduces the risk of sexually acquired HIV by over 99%.
Brand Descovy in New York pharmacies can exceed $1,800 per month without insurance. Tafero EM, manufactured in WHO-GMP certified facilities in India, delivers the same protection for a fraction of this cost — a critical option for uninsured New Yorkers and community health clinics across all five boroughs.
|
FAQ: Does Tafero EM work as well as brand-name PrEP medications? Yes. Tafero EM contains the exact same active ingredients — Emtricitabine and Tenofovir Alafenamide — at the same doses as brand Truvada and Descovy. Clinical equivalence between WHO-GMP certified generics and their branded counterparts has been extensively documented; the bioavailability and therapeutic effect are the same. The only difference is price, since generic manufacturers don't carry the same R&D and marketing costs as the original developer. |
